Therapeutic Drug Monitoring Market By Product (Consumables, Equipment), By Technology (Immunoassays, Chromatography-Spectrometry, Others), By Drug Class (Antiepileptic Drugs, Antiarrhythmic Drugs, Immunosuppressant Drugs, Antibiotic Drugs, Others), By End Users (Hospital, Diagnostic labs, Research and Academic Institutes): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global therapeutic drug monitoring market was valued at $1,932.93 million in 2021 and is projected to reach $4,415.3 million by 2031, registering a CAGR of 8.5% from 2022 to 2031. Therapeutic drug monitoring (TDM) is a clinical practice in which the concentration of a specific drug in a patient's blood is measured to optimize dosage regimens, and treatment, and minimize toxicity. Therapeutic drug monitoring is used to account for individual variability in drug metabolism, minimize the risk of toxicity, identify and manage drug interactions, and improve the safety and efficacy of drug treatment. It is a valuable tool in the management of drug treatment, offering numerous advantages in terms of safety, efficacy, and personalized care. Therapeutic drug concentration is monitored through immunoassays, calorimetric immunoassays, and chromatography-mass spectrometry.
The therapeutic drug monitoring market growth is driven by the growing prevalence of chronic diseases, an increase in awareness about therapeutic drug monitoring, and a rise in demand for therapeutic drug monitoring services in emerging markets. The rise in the prevalence of chronic diseases such as cardiovascular diseases, cancer, and neurodegenerative diseases, which require long-term treatment with drugs that have a narrow therapeutic window, is driving the demand for therapeutic drug monitoring services. For instance, according to International Diabetes Federation, in 2021, it was estimated that about 537 million adults (20-79 years) are living with diabetes in the world and is expected to reach 643 million by 2030. Thus, an increase in the prevalence of chronic diseases and the need for long-term treatment is expected to boost the demand for therapeutic drug monitoring services, which, in turn, contribute toward market growth. Furthermore, the increasing demand for advanced and innovative consumables such as immunoassays is the key factor contributing to the growth of the market. For instance, Eagle Biosciences offers various therapeutic drug monitoring assays such as Alemtuzumab ELISA Assay which is used for the quantitative determination of Alemtuzumab (Lemrada) drug in in the patient’s blood. However, a lack of skilled professionals present in the market, and technical errors in sample collection can limit the adoption of therapeutic drug monitoring products, which, in turn, hinders the growth of the market in upcoming years. On the other hand, increased focus on R&D activities for therapeutic drug monitoring and growth potential in emerging markets are expected to create immense opportunities for therapeutic drug monitoring during the forecast period.
The therapeutic drug monitoring market is segmented on the basis of product, technology, drug class, end user and region. As per product, the market is classified into consumables and equipment. On the basis of technology, the market is segmented into immunoassay, chromatography-spectrometry, and others. According to the drug class, the market is divided into anti-epileptic drugs, antibiotics drugs, anti-arrhythmic drugs, immunosuppressants, and others.
Depending on end-user, the market is classified into hospitals, diagnostic lab, and research and academic institutes. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA). Major key players that operate in the global therapeutic drug monitoring market are Abbott Laboratories, Biomerieux SA, Bio-Rad Laboratories, Inc., Chromsystems Instruments & Chemicals GmbH, Danaher Corporation, Exagen Inc, F. Hoffmann-La Roche Ltd., Sekisui Chemical Co Ltd., Siemens AG, and Thermo Fisher Scientific Inc.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the therapeutic drug monitoring market analysis from 2021 to 2031 to identify the prevailing therapeutic drug monitoring market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the therapeutic drug monitoring market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global therapeutic drug monitoring market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Technology
Immunoassays
Chromatography-Spectrometry
Others
By Product
Consumables
Equipment
By Drug Class
Antiepileptic Drugs
Antiarrhythmic Drugs
Immunosuppressant Drugs
Antibiotic Drugs
Others
By End Users
Hospital
Diagnostic labs
Research and Academic Institutes
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Biomerieux SA
Thermo Fisher Scientific Inc.
Siemens AG
Chromsystems Instruments & Chemicals GmbH
Bio-Rad Laboratories, Inc.
Danaher Corporation
SEKISUI CHEMICAL CO., LTD.
Exagen Inc.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Increase in the prevalence of chronic disease.
- 3.4.1.2. Rise in the adoption of precision medicine
- 3.4.1.3. Rise in technological advancement
- 3.4.2. Restraints
- 3.4.2.1. Lack of skilled professionals
- 3.4.3. Opportunities
- 3.4.3.1. High growth potential in developing economies
- 3.5. COVID-19 Impact Analysis on the market
- CHAPTER 4: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Consumables
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Equipment
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- CHAPTER 5: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Immunoassays
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Chromatography-Spectrometry
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- 5.4. Others
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
- CHAPTER 6: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Antiepileptic Drugs
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Antiarrhythmic Drugs
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Immunosuppressant Drugs
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- 6.5. Antibiotic Drugs
- 6.5.1. Key market trends, growth factors and opportunities
- 6.5.2. Market size and forecast, by region
- 6.5.3. Market share analysis by country
- 6.6. Others
- 6.6.1. Key market trends, growth factors and opportunities
- 6.6.2. Market size and forecast, by region
- 6.6.3. Market share analysis by country
- CHAPTER 7: THERAPEUTIC DRUG MONITORING MARKET, BY END USERS
- 7.1. Overview
- 7.1.1. Market size and forecast
- 7.2. Hospital
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by region
- 7.2.3. Market share analysis by country
- 7.3. Diagnostic labs
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by region
- 7.3.3. Market share analysis by country
- 7.4. Research and Academic Institutes
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by region
- 7.4.3. Market share analysis by country
- CHAPTER 8: THERAPEUTIC DRUG MONITORING MARKET, BY REGION
- 8.1. Overview
- 8.1.1. Market size and forecast By Region
- 8.2. North America
- 8.2.1. Key trends and opportunities
- 8.2.2. Market size and forecast, by Product
- 8.2.3. Market size and forecast, by Technology
- 8.2.4. Market size and forecast, by Drug Class
- 8.2.5. Market size and forecast, by End Users
- 8.2.6. Market size and forecast, by country
- 8.2.6.1. U.S.
- 8.2.6.1.1. Key market trends, growth factors and opportunities
- 8.2.6.1.2. Market size and forecast, by Product
- 8.2.6.1.3. Market size and forecast, by Technology
- 8.2.6.1.4. Market size and forecast, by Drug Class
- 8.2.6.1.5. Market size and forecast, by End Users
- 8.2.6.2. Canada
- 8.2.6.2.1. Key market trends, growth factors and opportunities
- 8.2.6.2.2. Market size and forecast, by Product
- 8.2.6.2.3. Market size and forecast, by Technology
- 8.2.6.2.4. Market size and forecast, by Drug Class
- 8.2.6.2.5. Market size and forecast, by End Users
- 8.2.6.3. Mexico
- 8.2.6.3.1. Key market trends, growth factors and opportunities
- 8.2.6.3.2. Market size and forecast, by Product
- 8.2.6.3.3. Market size and forecast, by Technology
- 8.2.6.3.4. Market size and forecast, by Drug Class
- 8.2.6.3.5. Market size and forecast, by End Users
- 8.3. Europe
- 8.3.1. Key trends and opportunities
- 8.3.2. Market size and forecast, by Product
- 8.3.3. Market size and forecast, by Technology
- 8.3.4. Market size and forecast, by Drug Class
- 8.3.5. Market size and forecast, by End Users
- 8.3.6. Market size and forecast, by country
- 8.3.6.1. Germany
- 8.3.6.1.1. Key market trends, growth factors and opportunities
- 8.3.6.1.2. Market size and forecast, by Product
- 8.3.6.1.3. Market size and forecast, by Technology
- 8.3.6.1.4. Market size and forecast, by Drug Class
- 8.3.6.1.5. Market size and forecast, by End Users
- 8.3.6.2. France
- 8.3.6.2.1. Key market trends, growth factors and opportunities
- 8.3.6.2.2. Market size and forecast, by Product
- 8.3.6.2.3. Market size and forecast, by Technology
- 8.3.6.2.4. Market size and forecast, by Drug Class
- 8.3.6.2.5. Market size and forecast, by End Users
- 8.3.6.3. UK
- 8.3.6.3.1. Key market trends, growth factors and opportunities
- 8.3.6.3.2. Market size and forecast, by Product
- 8.3.6.3.3. Market size and forecast, by Technology
- 8.3.6.3.4. Market size and forecast, by Drug Class
- 8.3.6.3.5. Market size and forecast, by End Users
- 8.3.6.4. Italy
- 8.3.6.4.1. Key market trends, growth factors and opportunities
- 8.3.6.4.2. Market size and forecast, by Product
- 8.3.6.4.3. Market size and forecast, by Technology
- 8.3.6.4.4. Market size and forecast, by Drug Class
- 8.3.6.4.5. Market size and forecast, by End Users
- 8.3.6.5. Spain
- 8.3.6.5.1. Key market trends, growth factors and opportunities
- 8.3.6.5.2. Market size and forecast, by Product
- 8.3.6.5.3. Market size and forecast, by Technology
- 8.3.6.5.4. Market size and forecast, by Drug Class
- 8.3.6.5.5. Market size and forecast, by End Users
- 8.3.6.6. Rest of Europe
- 8.3.6.6.1. Key market trends, growth factors and opportunities
- 8.3.6.6.2. Market size and forecast, by Product
- 8.3.6.6.3. Market size and forecast, by Technology
- 8.3.6.6.4. Market size and forecast, by Drug Class
- 8.3.6.6.5. Market size and forecast, by End Users
- 8.4. Asia-Pacific
- 8.4.1. Key trends and opportunities
- 8.4.2. Market size and forecast, by Product
- 8.4.3. Market size and forecast, by Technology
- 8.4.4. Market size and forecast, by Drug Class
- 8.4.5. Market size and forecast, by End Users
- 8.4.6. Market size and forecast, by country
- 8.4.6.1. Japan
- 8.4.6.1.1. Key market trends, growth factors and opportunities
- 8.4.6.1.2. Market size and forecast, by Product
- 8.4.6.1.3. Market size and forecast, by Technology
- 8.4.6.1.4. Market size and forecast, by Drug Class
- 8.4.6.1.5. Market size and forecast, by End Users
- 8.4.6.2. China
- 8.4.6.2.1. Key market trends, growth factors and opportunities
- 8.4.6.2.2. Market size and forecast, by Product
- 8.4.6.2.3. Market size and forecast, by Technology
- 8.4.6.2.4. Market size and forecast, by Drug Class
- 8.4.6.2.5. Market size and forecast, by End Users
- 8.4.6.3. Australia
- 8.4.6.3.1. Key market trends, growth factors and opportunities
- 8.4.6.3.2. Market size and forecast, by Product
- 8.4.6.3.3. Market size and forecast, by Technology
- 8.4.6.3.4. Market size and forecast, by Drug Class
- 8.4.6.3.5. Market size and forecast, by End Users
- 8.4.6.4. India
- 8.4.6.4.1. Key market trends, growth factors and opportunities
- 8.4.6.4.2. Market size and forecast, by Product
- 8.4.6.4.3. Market size and forecast, by Technology
- 8.4.6.4.4. Market size and forecast, by Drug Class
- 8.4.6.4.5. Market size and forecast, by End Users
- 8.4.6.5. South Korea
- 8.4.6.5.1. Key market trends, growth factors and opportunities
- 8.4.6.5.2. Market size and forecast, by Product
- 8.4.6.5.3. Market size and forecast, by Technology
- 8.4.6.5.4. Market size and forecast, by Drug Class
- 8.4.6.5.5. Market size and forecast, by End Users
- 8.4.6.6. Rest of Asia-Pacific
- 8.4.6.6.1. Key market trends, growth factors and opportunities
- 8.4.6.6.2. Market size and forecast, by Product
- 8.4.6.6.3. Market size and forecast, by Technology
- 8.4.6.6.4. Market size and forecast, by Drug Class
- 8.4.6.6.5. Market size and forecast, by End Users
- 8.5. LAMEA
- 8.5.1. Key trends and opportunities
- 8.5.2. Market size and forecast, by Product
- 8.5.3. Market size and forecast, by Technology
- 8.5.4. Market size and forecast, by Drug Class
- 8.5.5. Market size and forecast, by End Users
- 8.5.6. Market size and forecast, by country
- 8.5.6.1. Brazil
- 8.5.6.1.1. Key market trends, growth factors and opportunities
- 8.5.6.1.2. Market size and forecast, by Product
- 8.5.6.1.3. Market size and forecast, by Technology
- 8.5.6.1.4. Market size and forecast, by Drug Class
- 8.5.6.1.5. Market size and forecast, by End Users
- 8.5.6.2. Saudi Arabia
- 8.5.6.2.1. Key market trends, growth factors and opportunities
- 8.5.6.2.2. Market size and forecast, by Product
- 8.5.6.2.3. Market size and forecast, by Technology
- 8.5.6.2.4. Market size and forecast, by Drug Class
- 8.5.6.2.5. Market size and forecast, by End Users
- 8.5.6.3. South Africa
- 8.5.6.3.1. Key market trends, growth factors and opportunities
- 8.5.6.3.2. Market size and forecast, by Product
- 8.5.6.3.3. Market size and forecast, by Technology
- 8.5.6.3.4. Market size and forecast, by Drug Class
- 8.5.6.3.5. Market size and forecast, by End Users
- 8.5.6.4. Rest of LAMEA
- 8.5.6.4.1. Key market trends, growth factors and opportunities
- 8.5.6.4.2. Market size and forecast, by Product
- 8.5.6.4.3. Market size and forecast, by Technology
- 8.5.6.4.4. Market size and forecast, by Drug Class
- 8.5.6.4.5. Market size and forecast, by End Users
- CHAPTER 9: COMPETITIVE LANDSCAPE
- 9.1. Introduction
- 9.2. Top winning strategies
- 9.3. Product Mapping of Top 10 Player
- 9.4. Competitive Dashboard
- 9.5. Competitive Heatmap
- 9.6. Top player positioning, 2021
- CHAPTER 10: COMPANY PROFILES
- 10.1. Bio-Rad Laboratories, Inc.
- 10.1.1. Company overview
- 10.1.2. Key Executives
- 10.1.3. Company snapshot
- 10.1.4. Operating business segments
- 10.1.5. Product portfolio
- 10.1.6. Business performance
- 10.1.7. Key strategic moves and developments
- 10.2. Siemens AG
- 10.2.1. Company overview
- 10.2.2. Key Executives
- 10.2.3. Company snapshot
- 10.2.4. Operating business segments
- 10.2.5. Product portfolio
- 10.2.6. Business performance
- 10.3. F. Hoffmann-La Roche Ltd.
- 10.3.1. Company overview
- 10.3.2. Key Executives
- 10.3.3. Company snapshot
- 10.3.4. Operating business segments
- 10.3.5. Product portfolio
- 10.3.6. Business performance
- 10.4. Abbott Laboratories
- 10.4.1. Company overview
- 10.4.2. Key Executives
- 10.4.3. Company snapshot
- 10.4.4. Operating business segments
- 10.4.5. Product portfolio
- 10.4.6. Business performance
- 10.5. Biomerieux SA
- 10.5.1. Company overview
- 10.5.2. Key Executives
- 10.5.3. Company snapshot
- 10.5.4. Operating business segments
- 10.5.5. Product portfolio
- 10.5.6. Business performance
- 10.6. Danaher Corporation
- 10.6.1. Company overview
- 10.6.2. Key Executives
- 10.6.3. Company snapshot
- 10.6.4. Operating business segments
- 10.6.5. Product portfolio
- 10.6.6. Business performance
- 10.7. Exagen Inc.
- 10.7.1. Company overview
- 10.7.2. Key Executives
- 10.7.3. Company snapshot
- 10.7.4. Operating business segments
- 10.7.5. Product portfolio
- 10.7.6. Business performance
- 10.8. Thermo Fisher Scientific Inc.
- 10.8.1. Company overview
- 10.8.2. Key Executives
- 10.8.3. Company snapshot
- 10.8.4. Operating business segments
- 10.8.5. Product portfolio
- 10.8.6. Business performance
- 10.9. SEKISUI CHEMICAL CO., LTD.
- 10.9.1. Company overview
- 10.9.2. Key Executives
- 10.9.3. Company snapshot
- 10.9.4. Operating business segments
- 10.9.5. Product portfolio
- 10.9.6. Business performance
- 10.10. Chromsystems Instruments & Chemicals GmbH
- 10.10.1. Company overview
- 10.10.2. Key Executives
- 10.10.3. Company snapshot
- 10.10.4. Operating business segments
- 10.10.5. Product portfolio
- LIST OF TABLES
- TABLE 01. GLOBAL THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 02. THERAPEUTIC DRUG MONITORING MARKET FOR CONSUMABLES, BY REGION, 2021-2031 ($MILLION)
- TABLE 03. THERAPEUTIC DRUG MONITORING MARKET FOR EQUIPMENT, BY REGION, 2021-2031 ($MILLION)
- TABLE 04. GLOBAL THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 05. THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY REGION, 2021-2031 ($MILLION)
- TABLE 06. THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-SPECTROMETRY, BY REGION, 2021-2031 ($MILLION)
- TABLE 07. THERAPEUTIC DRUG MONITORING MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 08. GLOBAL THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 09. THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY REGION, 2021-2031 ($MILLION)
- TABLE 10. THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY REGION, 2021-2031 ($MILLION)
- TABLE 11. THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY REGION, 2021-2031 ($MILLION)
- TABLE 12. THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY REGION, 2021-2031 ($MILLION)
- TABLE 13. THERAPEUTIC DRUG MONITORING MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 14. GLOBAL THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 15. THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL, BY REGION, 2021-2031 ($MILLION)
- TABLE 16. THERAPEUTIC DRUG MONITORING MARKET FOR DIAGNOSTIC LABS, BY REGION, 2021-2031 ($MILLION)
- TABLE 17. THERAPEUTIC DRUG MONITORING MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2021-2031 ($MILLION)
- TABLE 18. THERAPEUTIC DRUG MONITORING MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 19. NORTH AMERICA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 20. NORTH AMERICA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 21. NORTH AMERICA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 22. NORTH AMERICA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 23. NORTH AMERICA THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 24. U.S. THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 25. U.S. THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 26. U.S. THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 27. U.S. THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 28. CANADA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 29. CANADA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 30. CANADA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 31. CANADA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 32. MEXICO THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 33. MEXICO THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 34. MEXICO THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 35. MEXICO THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 36. EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 37. EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 38. EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 39. EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 40. EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 41. GERMANY THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 42. GERMANY THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 43. GERMANY THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 44. GERMANY THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 45. FRANCE THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 46. FRANCE THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 47. FRANCE THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 48. FRANCE THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 49. UK THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 50. UK THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 51. UK THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 52. UK THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 53. ITALY THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 54. ITALY THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 55. ITALY THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 56. ITALY THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 57. SPAIN THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 58. SPAIN THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 59. SPAIN THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 60. SPAIN THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 61. REST OF EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 62. REST OF EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 63. REST OF EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 64. REST OF EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 65. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 66. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 67. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 68. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 69. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 70. JAPAN THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 71. JAPAN THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 72. JAPAN THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 73. JAPAN THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 74. CHINA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 75. CHINA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 76. CHINA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 77. CHINA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 78. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 79. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 80. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 81. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 82. INDIA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 83. INDIA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 84. INDIA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 85. INDIA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 86. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 87. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 88. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 89. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 90. REST OF ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 91. REST OF ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 92. REST OF ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 93. REST OF ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 94. LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 95. LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 96. LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 97. LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 98. LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 99. BRAZIL THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 100. BRAZIL THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 101. BRAZIL THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 102. BRAZIL THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 103. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 104. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 105. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 106. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 107. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 108. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 109. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 110. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 111. REST OF LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 112. REST OF LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 113. REST OF LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 114. REST OF LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
- TABLE 115. BIO-RAD LABORATORIES, INC.: KEY EXECUTIVES
- TABLE 116. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
- TABLE 117. BIO-RAD LABORATORIES, INC.: PRODUCT SEGMENTS
- TABLE 118. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
- TABLE 119. BIO-RAD LABORATORIES, INC.: KEY STRATERGIES
- TABLE 120. SIEMENS AG: KEY EXECUTIVES
- TABLE 121. SIEMENS AG: COMPANY SNAPSHOT
- TABLE 122. SIEMENS AG: PRODUCT SEGMENTS
- TABLE 123. SIEMENS AG: PRODUCT PORTFOLIO
- TABLE 124. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
- TABLE 125. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
- TABLE 126. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
- TABLE 127. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
- TABLE 128. ABBOTT LABORATORIES: KEY EXECUTIVES
- TABLE 129. ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 130. ABBOTT LABORATORIES: PRODUCT SEGMENTS
- TABLE 131. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 132. BIOMERIEUX SA: KEY EXECUTIVES
- TABLE 133. BIOMERIEUX SA: COMPANY SNAPSHOT
- TABLE 134. BIOMERIEUX SA: PRODUCT SEGMENTS
- TABLE 135. BIOMERIEUX SA: PRODUCT PORTFOLIO
- TABLE 136. DANAHER CORPORATION: KEY EXECUTIVES
- TABLE 137. DANAHER CORPORATION: COMPANY SNAPSHOT
- TABLE 138. DANAHER CORPORATION: PRODUCT SEGMENTS
- TABLE 139. DANAHER CORPORATION: PRODUCT PORTFOLIO
- TABLE 140. EXAGEN INC.: KEY EXECUTIVES
- TABLE 141. EXAGEN INC.: COMPANY SNAPSHOT
- TABLE 142. EXAGEN INC.: PRODUCT SEGMENTS
- TABLE 143. EXAGEN INC.: PRODUCT PORTFOLIO
- TABLE 144. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
- TABLE 145. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
- TABLE 146. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS
- TABLE 147. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
- TABLE 148. SEKISUI CHEMICAL CO., LTD.: KEY EXECUTIVES
- TABLE 149. SEKISUI CHEMICAL CO., LTD.: COMPANY SNAPSHOT
- TABLE 150. SEKISUI CHEMICAL CO., LTD.: PRODUCT SEGMENTS
- TABLE 151. SEKISUI CHEMICAL CO., LTD.: PRODUCT PORTFOLIO
- TABLE 152. CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH: KEY EXECUTIVES
- TABLE 153. CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH: COMPANY SNAPSHOT
- TABLE 154. CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH: PRODUCT SEGMENTS
- TABLE 155. CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH: PRODUCT PORTFOLIO
- LIST OF FIGURES
- FIGURE 01. THERAPEUTIC DRUG MONITORING MARKET, 2021-2031
- FIGURE 02. SEGMENTATION OF THERAPEUTIC DRUG MONITORING MARKET, 2021-2031
- FIGURE 03. TOP INVESTMENT POCKETS IN THERAPEUTIC DRUG MONITORING MARKET (2022-2031)
- FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
- FIGURE 05. LOW BARGAINING POWER OF BUYERS
- FIGURE 06. LOW THREAT OF SUBSTITUTES
- FIGURE 07. LOW THREAT OF NEW ENTRANTS
- FIGURE 08. LOW INTENSITY OF RIVALRY
- FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALTHERAPEUTIC DRUG MONITORING MARKET
- FIGURE 10. THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021(%)
- FIGURE 11. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR CONSUMABLES, BY COUNTRY 2021-2031(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR EQUIPMENT, BY COUNTRY 2021-2031(%)
- FIGURE 13. THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021(%)
- FIGURE 14. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY COUNTRY 2021-2031(%)
- FIGURE 15. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-SPECTROMETRY, BY COUNTRY 2021-2031(%)
- FIGURE 16. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
- FIGURE 17. THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021(%)
- FIGURE 18. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY COUNTRY 2021-2031(%)
- FIGURE 19. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY COUNTRY 2021-2031(%)
- FIGURE 20. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY COUNTRY 2021-2031(%)
- FIGURE 21. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY COUNTRY 2021-2031(%)
- FIGURE 22. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
- FIGURE 23. THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021(%)
- FIGURE 24. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL, BY COUNTRY 2021-2031(%)
- FIGURE 25. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR DIAGNOSTIC LABS, BY COUNTRY 2021-2031(%)
- FIGURE 26. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY 2021-2031(%)
- FIGURE 27. THERAPEUTIC DRUG MONITORING MARKET BY REGION, 2021
- FIGURE 28. U.S. THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
- FIGURE 29. CANADA THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
- FIGURE 30. MEXICO THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
- FIGURE 31. GERMANY THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
- FIGURE 32. FRANCE THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
- FIGURE 33. UK THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
- FIGURE 34. ITALY THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
- FIGURE 35. SPAIN THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
- FIGURE 36. REST OF EUROPE THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
- FIGURE 37. JAPAN THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
- FIGURE 38. CHINA THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
- FIGURE 39. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
- FIGURE 40. INDIA THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
- FIGURE 41. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
- FIGURE 42. REST OF ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
- FIGURE 43. BRAZIL THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
- FIGURE 44. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook